No Data
No Data
Earnings Preview: CHRS to Report Financial Results Post-market on May 12
Coherus to Report First Quarter 2025 Financial Results on May 12, 2025
Coherus to Participate in Upcoming Investor Conferences
H.C. Wainwright Maintains Coherus BioSciences(CHRS.US) With Buy Rating, Maintains Target Price $7
Express News | HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $7 Price Target
Promising Clinical Data and Strategic Expansion Justify Buy Rating for Coherus Biosciences